文献速递银屑病与炎症性皮肤病

乌司奴单抗停药后阿巴西普阻断共刺激信号对中重度斑块状银屑病复发的影响:PAUSE随机临床试验

Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2021-01-01

PAUSE试验在美国和加拿大10个中心纳入108例中重度斑块状银屑病成人患者,经乌司奴单抗导入后91例应答者随机分为继续乌司奴单抗组或换用阿巴西普组,第39周停药随访至第88周。

要点

  • 阿巴西普不能预防乌司奴单抗停药后的银屑病复发。
  • 阿巴西普组与乌司奴单抗组复发率及中位复发时间均无显著差异。
  • 阿巴西普未能维持IL-23介导的银屑病分子特征抑制,血清IL-19升高。

核心结论

  • 阿巴西普未能预防乌司奴单抗停药后的银屑病复发,因其未完全阻断导致复发的致病性银屑病分子通路。

研究设计与样本

  • PAUSE为平行设计、双盲、安慰剂对照随机临床试验,在美国和加拿大10个中心开展,2014年3月19日至2016年4月11日入组。
  • 108例中重度斑块状银屑病成人接受开放标签乌司奴单抗导入,第12周应答的91例按1:1随机分为继续乌司奴单抗组或换用阿巴西普组。
  • 第39周停止治疗,随访至第88周观察复发,统计分析基于意向治疗(ITT)和安全样本。

主要发现

  • 末次乌司奴单抗剂量后中位复发时间:阿巴西普组36周(95%CI,36-48周),乌司奴单抗组32周(95%CI,28-40周)。
  • 两组不良事件数量和发生率相似。
  • 阿巴西普未维持乌司奴单抗停药后皮损中致病性IL-23介导的银屑病分子特征抑制,血清IL-19水平升高。

临床怎么用

  • 对于中重度斑块状银屑病,乌司奴单抗停药后换用阿巴西普不能作为预防复发的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psoriasis relapse may involve compensatory T-cell activation pathways in the presence of CD28-CD80/CD86 blockade with abatacept. OBJECTIVE: To determine whether costimulatory signaling blockade with abatacept prevents psoriasis relapse after ustekinumab withdrawal. DESIGN, SETTING, AND PARTICIPANTS: Psoriasis Treatment with Abatacept and Ustekinumab: a Study of Efficacy (PAUSE), a parallel-design, double-blind, placebo-controlled randomized clinical trial, was conducted at 10 sites in the US and Canada. Participant enrollment opened on March 19, 2014, and concluded on April 11, 2016. Participants were adults with moderate to severe plaque psoriasis and received ustekinumab in a lead-in phase. Those who responded to ustekinumab at week 12 were randomized 1:1 to either the continued with ustekinumab group (ustekinumab group) or the switched to abatacept group (abatacept group). Treatment was discontinued at week 39, and participants were followed up for psoriasis relapse until week 88. Statistical analyses were performed in the intention-to-treat (ITT) and safety samples from May 3, 2018, to July 6, 2021. INTERVENTIONS: Participants received subcutaneous ustekinumab at weeks 0 and 4 (45 mg per dose for those ≤100 kg; 90 mg per dose for those >100 kg). Participants randomized to the abatacept group at week 12 received subcutaneous abatacept, 125 mg weekly, from weeks 12 to 39 and ustekinumab placebo at weeks 16 and 28. Participants randomized to the ustekinumab group received ustekinumab at weeks 16 and 28 and abatacept placebo weekly from weeks 12 to 39. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of participants with psoriasis relapse (loss of ≥50% of the initial Psoriasis Area and Severity Index improvement) between weeks 12 and 88. Secondary end points included time to psoriasis relapse, proportion of participants with psoriasis relapse between weeks 12 and 40, and adverse events. The psoriasis transcriptome and serum cytokines were evaluated. RESULTS: A total of 108 participants (mean [SD] age, 46.1 [12.1] years; 73 [67.6%] men) were treated with open-label ustekinumab; 91 were randomized to blinded treatment. Similar proportions of participants in the abatacept group and the ustekinumab group relapsed between weeks 12 and 88 (41 of 45 [91.1%] vs 40 of 46 [87.0%]; P = .41). Median time to relapse from the last dose of ustekinumab was similar between groups as well: 36 weeks (95% CI, 36-48 weeks) in the abatacept group vs 32 weeks (95% CI, 28-40 weeks) in the ustekinumab group. Similar numbers and rates of adverse events occurred. Abatacept did not maintain suppression of the pathogenic IL-23-mediated psoriasis molecular signature in lesions after ustekinumab withdrawal, and serum IL-19 levels increased. CONCLUSIONS AND RELEVANCE: This parallel-design, double-blind randomized clinical trial found that abatacept did not prevent psoriasis relapse that occurred after ustekinumab withdrawal because it did not completely block the pathogenic psoriasis molecular pathways that led to relapse. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01999868.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Harris KM, Smilek DE, Byron M, et al. Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial. JAMA Dermatol. 2021. PMID: 34643650. doi:10.1001/jamadermatol.2021.3492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。